Treatment of patients with acromegaly in whom surgery is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective (see section 4.2). Treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours e.g. carcinoid tumours with features of the carcinoid syndrome (see section 5.1). Treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded. Treatment of TSH-secreting pituitary adenomas: • when secretion has not normalised after surgery and/or radiotherapy; • in patients in whom surgery is inappropriate; • in irradiated patients, until radiotherapy is effective.
Results of the largest Phase III study of Acromegaly patients, PASPORT-ACROMEGALY, show the novel therapy Signifor ( pasireotide) long-acting release...
Symptomatic control and reduction of growth hormone (GH) and IGF-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. Sandostatin is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. Relief of symptoms associated with functional gastro-entero-pancreatic (GEP) endocrine tumours, e.g. carcinoid tumours with features of the carcinoid syndrome (see section 5.1). Sandostatin is not an anti-tumour therapy and is not curative in these patients. Prevention of complications following pancreatic surgery. Emergency management to stop bleeding and to protect from re-bleeding owing to gastro-oesophageal varices in patients with cirrhosis. Sandostatin is to be used in association with specific treatment such as endoscopic sclerotherapy. Treatment of TSH-secreting pituitary adenomas: • when secretion has not normalised after surgery and/or radiotherapy; • in patients in whom surgery is inappropriate; • in irradiated patients, until radiotherapy is effective.
Advanced Accelerator Applications announced today at ECC 2015 that the pivotal Phase III NETTER-1 study for Lutathera (177Lu-DOTATATE) met its...
The FDA has accepted for filing the NDA for the marketing and sale of octreotide capsules from Chiasma Pharma for...
Novartis announced that the FDA has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the...
Novartis presented results from a pivotal Phase III trial of investigational therapy Signifor LAR (pasireotide LAR; SOM230) in patients with...
Recordati announced the successful completion of the acquisition from Novartis of worldwide rights to Signifor and Signifor LAR for the...